This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Joe's Jeans, Vivus: Volume Movers

BOSTON ( TheStreet) -- Joe's Jeans (JOEZ - Get Report) was one of several stocks trading near $5 poised to move on above-average volume Friday after the company reported second-quarter results and said it expects gross margins to increase going forward.

Joe's Jeans said it had a second-quarter profit of a penny a share on revenue of $25.9 million, compared with the Thomson Reuters average estimate for earnings of a penny a share on sales of $23.1 million. The company said that it expects to see "a meaningful lift" in gross margins as it grows new product categories.

Shares of Joe's Jeans jumped by 13 cents, or 6.3%, to $2.20 in Thursday's after-market session. The average daily share volume for Joe's Jeans is 1.04 million.

Elsewhere, Vivus (VVUS - Get Report) shares plunged by $6.71, or 55.4%, to $5.40 in the premarket session after a U.S. Food and Drug Administration advisory panel rejected the company's weight-loss drug Qnexa by a final 10-6 vote on concerns about the drug's long-term safety. The average daily share volume for Vivus is 6.62 million.

On the other hand, Arena Pharmaceuticals shares were rallying in Friday's premarket session, climbing 14.3% to $4.48. TheStreet's Adam Feuerstein writes that Arena already has two-year safety data on its own weight-loss drug lorcaserin that has not yet raised any alarm bells. An FDA advisory panel will meet on Sept. 16 to review lorcaserin, with an FDA approval decision date of Oct. 22.

Analysts have the same view. On Friday, JPMorgan cut Vivus to neutral from overweight while the firm upgraded Arena to overweight from neutral. Needham & Co., Brean Murray and Jefferies analysts also downgraded shares of Vivus Friday on the FDA panel's decision.

Riverview Bancorp (RVSB - Get Report) rallied by 28 cents, or 12.1%, to $2.63 late Thursday after the company reported first-quarter net income of 16 cents a share, rising sharply from a year-ago profit of 3 cents a share. The bank said it saw improvements in net interest margin, deposit growth, capital levels and credit metrics during the quarter. The average daily share volume for Riverview is 7,000.

SandRidge Energy (SD - Get Report) climbed by 42 cents, or 6.5%, to $6.89 in the premarket session after the natural gas and oil company said it will sell certain deep acreage rights in Oklahoma to an independent oil and gas company for $140 million in cash. SandRidge, which is merging with Arena Resources (ARD), said the transaction should close in the third quarter. The average daily share volume for SandRidge Energy is 6.54 million.

Tongxin International (TXIC) sank by 22 cents, or 4.7%, to $4.49 in Thursday's late trading session after the company said in an update to shareholders that it will miss the filing deadline for its 2009 audit. The company previously asked for an extension of the 20-F deadline on July 1. Tongxin said that it is determining the appropriate accounting treatment of certain related-party transactions of approximately $7.7 million.

The company did say it expects to report full-year 2009 revenues of $121.6 million, which would below the consensus target of $122.1 million. The average daily share volume for Tongxin is 80,000.

-- Written by Robert Holmes in Boston.

Check out all of Friday's high-volume, under-$5 stocks at the Dollar Store. View the Dollar Store portfolio on StockPickr.

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
TXIC $0.04 -8.89%
ARNA $3.92 -1.51%
JOEZ $0.15 9.89%
SD $1.22 1.67%
RVSB $4.14 0.73%

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs